ESALF News and Press, Eisai Co Ltd From 06/28/24

Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China TOKYO and CAMBRIDGE, Mass., June 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the humanized anti-soluble aggregated amyloid-beta (Abeta) monoclo...

2024-06-22 11:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity Eli Lilly And Alzheimer's Disease: The Paucity Of Progress ResMed, Philips under pressur...

Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City TOKYO, June 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo Cit...

2024-06-17 17:58:14 ET Summary An FDA advisory committee voted 11-0 in favor of Eli Lilly and Company's donanemab for the treatment of early Alzheimer's disease. Donanemab has no effect on non-APOE4 carriers, may slow the decline of APOE4 carriers closer to that of non-carriers, a...

2024-06-10 12:09:47 ET More on Biogen, Eisai , etc. Biogen Inc. (BIIB) Q1 2024 Earnings Call Transcript Eisai Co Ltd. (ESALF) Q4 2024 Earnings Call Transcript Biogen: Reasons To Be Cheerful After Upbeat Q1 Earnings Lilly's donanemab, remternetug set to d...

FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., June 10, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today tha...

2024-06-06 10:09:40 ET More on Eli Lilly Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs? Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly snaps six straight...

2024-06-05 13:10:12 ET More on Biogen, Eli Lilly, etc. Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Alphabet taps...

Eisai Named to List of The Time 100 Most Influential Companies TOKYO, June 3, 2024 - (JCN Newswire) - TIME reveals the TIME100 Most Influential Companies list, highlighting companies making an extraordinary impact around the world. To assemble the list, TIME solicited nominations ac...

Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform TOKYO, June 3, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company decided to strengthen and continue its venture investment bus...